GSK buys US cancer drugmaker Tesaro for hefty $5.1bn
GSK has fallen behind rivals in producing multibillion-dollar blockbusters
GlaxoSmithKline abandons plans for new plant in Cumbria
Cantillon: Brexit decision may be giving Big Pharma doubts about British location
Glaxo to pay first woman boss 25% less than male predecessor
Emma Walmsley’s lack of experience cited as justification for salary
Sterling plunge boosts Glaxo profits but generics pose real threat
Pharma concerned that alternative to Advair will be approved in US
GSK takes case against Pfizer over meningococcal vaccine
GSK’s Bexsero the only vaccine for now and is struggling to meet demand
GlaxoSmithKline appoints Walmsley as chief executive
Walmsley will succeed Andrew Witty when he retires
GlaxoSmithKline invests £275m in UK despite Brexit vote
Drugmaker had argued against UK exit from EU over fears about drug regulation
GlaxoSmithKline rebound gathers pace as underlying profit jumps 14%
Consumer profit margins rise to 17% from 12% in the previous three months as CEO says company could achieve target of 20% or more ahead of 2020 target
European markets dragged down as euro strengthens against dollar
Swiss-Irish food group Aryzta rounds off difficult few days with modest decline
GSK chief asks for three years for profit increase
Andrew Witty tells investors he will improve profitability at Glaxo’s consumer unit
GlaxoSmithKline beats profit forecasts despite Advair hit and lower margins
CEO Witty focuses on depth of research pipeline which features around 40 potential new drugs and vaccines
Novartis, GSK complete deals to reshape both drugmakers
GSK to receive net after tax proceeds of $7.8 bn
WHO expects around 200,000 Ebola vaccine doses by mid-2015
Trócaire chief says there is a window of six weeks to bring crisis under control
China jails British detective hired by GSK to investigate sex tape
Peter Humphrey convicted of illegally obtaining personal details of Chinese citizens
Poor lung drug sales hit GSK in first quarter
Chief executive Witty steps back from AstraZeneca battle, declairing caution on mega deals
Deals and rumours of deals send pharma sector into a spin
London Briefing: major drug shares in UK soar on talk of mergers, acquisitions and asset swaps
Deals fever grips pharma industry
Transactions worth $140bn so far this year include asset swap between Novartis and GlaxoSmithKline
GlaxoSmithKline signals better 2014 as drug R&D improves
The prediction does not take into account the negative impact of a strengthening pound
GlaxoSmithKline to stop paying doctors to promote drugs
Firm also plans to stop tying compensation of sales reps to prescriptions written
Bribery scandal slashes GlaxoSmithKline’s Chinese drug sales
China sales slump 61% as doctors shun GSK products
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices